<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366479">
  <stage>Registered</stage>
  <submitdate>5/06/2014</submitdate>
  <approvaldate>2/07/2014</approvaldate>
  <actrnumber>ACTRN12614000697684</actrnumber>
  <trial_identification>
    <studytitle>The adjuvant effect of metformin and N-acetylcysteine to clomiphene citrate in induction of ovulation and pregnancy rate in patients with Polycystic Ovary Syndrome</studytitle>
    <scientifictitle>The adjuvant effect of metformin and N-acetylcysteine to clomiphene citrate in induction of ovulation and pregnancy rate in patients with Polycystic Ovary Syndrome.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Polycystic Ovary Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>120 women with PCOS were randomly divided to 3 groups: group I (40 women) received clomiphene citrate (CC) only100 mg orally in two divided doses from day 3 until day 7 of the menstrual cycle, group II (40 women) received CC 100 mg orally in two divided doses from day 3 until day 7 of the menstrual cycle plus N-acetyl cysteine (NAC) 1200 mg orally  in two divided doses in the form of powder inserted in small pockets to be diluted into one standard glass of water from day 3 until day 7 of the menstrual cycle and group III (40 women) received CC 100 mg orally in two divided doses from day 3 until day 7 of the menstrual cycle plus metformin 500 mg orally three times daily continuously for 4 weeks
Monitoring through  A transvaginal ultrasonography (TVS) using Toshiba femio 5 (Toshiba Medical Solutions Inc., Ultrasound Division, Japan) equipped with a 6.5 MHz transvaginal transducer  on alternate days starting from cycle day 9 till ovulation to determine the follicular number, size, endometrial thickness and pattern and evidence of follicular rupture. </interventions>
    <comparator> the CC only treatment is the control arm.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>pregnancy rate (clinical pregnancy defined as the presence of gestational sac containing fetal heartbeats on ultrasound scan)</outcome>
      <timepoint>2 weeks after missed period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>endometrial thickness measured by transvaginal ultrasound</outcome>
      <timepoint>at Baseline and every 2 days till ovulation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>size of follicles measured by transvaginal ultrasound</outcome>
      <timepoint>at Baseline and every 2 days till ovulation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>women with PCOS trying to fall pregnant</inclusivecriteria>
    <inclusiveminage>19</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. women with endocrinological abnormalities as thyroid dysfunction or abnormal prolactin levels
2. women with hypothalamic or pituitary dysfunctions 
3. women with other causes of infertility as tubal factor,  abnormal uterine cavity and male factor evaluated. 
4.Women with ovarian cysts
5.women with allergy to used medications. 
6. Patients who had received any hormonal medications (except progesterone for withdrawal bleeding) for at least 3 months before the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/09/2012</anticipatedstartdate>
    <actualstartdate>1/09/2012</actualstartdate>
    <anticipatedenddate>31/03/2014</anticipatedenddate>
    <actualenddate>31/03/2014</actualenddate>
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Cairo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Ahmed  Maged </primarysponsorname>
    <primarysponsoraddress>Kasr Alaini medical school. 135 King Faisal Street Haram Giza
postal code 12151</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Ahmed  Maged </fundingname>
      <fundingaddress>135 King Faisal Street Haram Giza postal code 12151

</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Aly Abdelhafez </sponsorname>
      <sponsoraddress>Kasr Alaini medical school. 420 Haram street Haram Giza.postal code 12163</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>to assess the adjuvant effect of metformine and N-acetylcysteine to clomiphene citrate in induction of ovulation in patients with PCOS</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Cairo university </ethicname>
      <ethicaddress>22 Kasr Alaini street Cairo.postal code 12254</ethicaddress>
      <ethicapprovaldate>7/07/2012</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/06/2014</ethicsubmitdate>
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Ahmed Maged</name>
      <address>Kasr Alaini medical school. 135 King Faisal Street Haram Giza. Postal code 12151
</address>
      <phone>+20201005227404</phone>
      <fax />
      <email>prof.ahmedmaged@gmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Ahmed Maged</name>
      <address>Kasr Alaini medical school. 135 King Faisal Street Haram Giza. Postal code 12151</address>
      <phone>+20201005227404</phone>
      <fax />
      <email>prof.ahmedmaged@gmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Ahmed Maged</name>
      <address>Kasr Alaini medical school. 135 King Faisal Street Haram Giza. Postal code 12151</address>
      <phone>+20201005227404</phone>
      <fax />
      <email>prof.ahmedmaged@gmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Ahmed Maged</name>
      <address>135 King Faisal Street Haram Giza</address>
      <phone>+20201005227404</phone>
      <fax />
      <email>prof.ahmedmaged@gmail.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>